FDA review
UCB’s psoriasis drug application overcomes manufacturing hurdle but hits another FDA delay
Anika Sharma
After facing delays related to manufacturing issues, UCB’s psoriasis medication, bimekizumab, is awaiting the next steps in its FDA review ...
